Pregabalin Capsule
Product Images NDC 71610-719

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 150 mg (71610 0719 30)

Bottle Label 150 mg (71610 0719 30)
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical Structure (Pregabalin 01)
FDA Label Image

Figure 1 (Pregabalin 02)

Figure 1 (Pregabalin 02)
The text is not readable.*
FDA Label Image

Figure 2 (Pregabalin 03)

Figure 2 (Pregabalin 03)
FDA Label Image

Figure 3 (Pregabalin 04)

Figure 3 (Pregabalin 04)
FDA Label Image

Figure 4 (Pregabalin 05)

Figure 4 (Pregabalin 05)
This text provides information on a medication called Pregabalin. It suggests that Pregabalin is taken at a dosage of 200 mg three times a day. There is also a mention of a lower dosage option of 100 mg three times a day. Additionally, there is a reference to a placebo. The remaining text appears to be related to the percentage of patients who experienced improvements in pain levels from baseline.*
FDA Label Image

Figure 5 (Pregabalin 06)

Figure 5 (Pregabalin 06)
FDA Label Image

Figure 6 (Pregabalin 07)

Figure 6 (Pregabalin 07)
FDA Label Image

Figure 7 (Pregabalin 08)

Figure 7 (Pregabalin 08)
FDA Label Image

Figure 9 (Pregabalin 09)

Figure 9 (Pregabalin 09)
FDA Label Image

Figure 10 (Pregabalin 10)

Figure 10 (Pregabalin 10)
FDA Label Image

Figure 11 (Pregabalin 11)

Figure 11 (Pregabalin 11)
This information provides a chart showing the percent of subjects improved over a period of time. The data includes a range of values (210, 220, 230, 240, 250, 260, 270, 280, 290) along with a corresponding percentage value (70%). It also mentions the improvement from baseline to week 12, comparing two groups: one receiving pregabalin and the other receiving a placebo.*
FDA Label Image

Figure 12 (Pregabalin 12)

Figure 12 (Pregabalin 12)
The text provided does not contain any readable information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.